In Brief: Dianon Systems
This article was originally published in The Gray Sheet
Dianon Systems: Firm plans to pursue non-exclusive licenses to a patent recently issued to Dianon and a co-owner, Medicorp, related to a testing method that measures both "total" and "free" forms of prostate-specific antigen (PSA). Dianon is seeking licenses from both clinical labs and kit manufacturers...
You may also be interested in...
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.